<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://dirros.openscience.si/IzpisGradiva.php?id=24748"><dc:title>Detection of specific antibodies against SARS-CoV-2 spike protein via ultra-sensitive bio-functionalized carbonnitride-reduced graphene oxide electrochemical immunosensing platform in real samples</dc:title><dc:creator>Abubakar Sadique,	Mohd.	(Avtor)
	</dc:creator><dc:creator>Yadav,	Shalu	(Avtor)
	</dc:creator><dc:creator>Ranjan,	Pushpesh	(Avtor)
	</dc:creator><dc:creator>Chouhan,	Raghuraj S.	(Avtor)
	</dc:creator><dc:creator>Jerman,	Ivan	(Avtor)
	</dc:creator><dc:creator>Kumar,	Ashok	(Avtor)
	</dc:creator><dc:creator>Saigal,	Saurabh	(Avtor)
	</dc:creator><dc:creator>Khadanga,	Sagar	(Avtor)
	</dc:creator><dc:creator>Khan,	Raju	(Avtor)
	</dc:creator><dc:creator>Srivastava,	Avanish K.	(Avtor)
	</dc:creator><dc:subject>SARS-CoV-2</dc:subject><dc:subject>detection</dc:subject><dc:subject>nanomaterials</dc:subject><dc:description>In this work, we fabricate a facile de novo synthesis route to prepare bio-functionalized carbon nitride-reduced graphene oxide with chitosan (Chi) nanocomposite (C3N4/RGO/Chi). The nitrogen-rich C3N4 has been synthesized through facile and low-cost thermal oxidation and offers a metal-free and highly active surface for synergistic modification with RGO and Chi. Moreover, the synergistically incorporated C3N4/RGO and biopolymer improve the electrocatalytic activity, provide surface functionalities, and enhance electroconductivity for immunosensing applications. Consequently, the bio-functionalized C3N4/RGO nanocomposite provides a suitable substrate for the immobilization of SARS-CoV-2 RBD spike protein. The immunosensor detects SARS-CoV-2 antibodies in a wide detection range from 10 zg mL−1 (10 × 10−21 g mL−1) to 100 ng mL−1 with an ultra-low detection limit (LOD) of 3.31 zg mL−1. The validation of the immunosensor was also carried out on spiked serum samples, which show a linear detection range of 100 ag mL−1 to 100 ng mL−1 and a LOD of 1.73 ag mL−1. Nevertheless, the clinical diagnostic application of the immunosensor is validated through the examination of real serum samples from COVID-19 patients. The results suggest that the immunosensor can be efficiently used as a screening platform to distinguish between positive and negative samples with high accuracy. The findings of the work have the potential to translate the immunosensing strategy into next-generation point-of-care testing (POCT) of various infectious diseases.</dc:description><dc:publisher>The Royal Society of Chemistry</dc:publisher><dc:date>2023</dc:date><dc:date>2025-12-16 13:46:30</dc:date><dc:type>Neznano</dc:type><dc:identifier>24748</dc:identifier><dc:source>Združeno kraljestvo</dc:source><dc:language>sl</dc:language><dc:rights>© 2023 The Author(s).</dc:rights></rdf:Description></rdf:RDF>
